New Whitepaper Explores How Malvern Instruments Extends a QbD Approach to Instrument Design
‘Extending the boundaries of QbD’, a new whitepaper from Malvern Instruments, explores the application of Quality by Design (QbD) principles to the development of analytical instrumentation and the benefits this brings for users. Taking the example of Malvern’s development of the Mastersizer 3000 particle size analyser, the authors illustrate how instrument companies are aligning with the QbD philosophy. This offers pharmaceutical customers the reassurance of closely similar working practices and products that meet exacting customer standards.
The central idea of QbD is that quality should be built into a product from the outset. It is an approach based on the development of a thorough understanding of the variables that affect performance, quantification of the risks associated with those impacts, and knowledge-based risk mitigation. Taking a similar risk assessment-based QbD approach to instrument design builds consistency and performance into a product from the outset. This thought and knowledge translates directly into an analytical tool that is not only reliable and compliant with regulatory requirements but is also efficient, productive and easy to use.
The starting point for QbD is the clear definition of a target performance profile for the product. The design of the Mastersizer 3000 began with a rigorous assessment of industrial requirements for particle size analysis and, since the product is wrapped by a cycle of continuous improvement, that assessment continues today. The third anniversary of the instrument has been marked with the launch of two new products that deliver even smarter particle sizing. Hydro Sight is a state-of-the-art imaging accessory that makes it quicker and easier to develop and apply the robust particle sizing methods that are essential across industry, by delivering real-time visual monitoring of the dispersion process that precedes every laser diffraction particle size measurement. Hydro SV is a wet dispersion accessory that enables measurement with just a few milligrams of sample.
To download ‘Extending the boundaries of QbD’ from the Malvern website, click here.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.